{"classes":[{"categories":[{"measurements":[{"comment":"Data not estimable due to the low number of events","groupId":"OG000","lowerLimit":"7.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Time to hematological relapse was measured from the start of treatment with blinatumomab until hematological or extramedullary relapse. Participants who died or received HSCT or post-blinatumomab chemotherapy after treatment with blinatumomab were censored at their last hematological assessment prior to death or HSCT or post-blinatumomab chemotherapy (whichever occurred first).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set participants who were in hematological complete remission at treatment start, excluding Philadelphia-positive participants.","reportingStatus":"POSTED","timeFrame":"Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.","title":"Time to Hematological Relapse","type":"SECONDARY","unitOfMeasure":"months"}